Exagen Inc. Stock Price, News & Analysis

Exagen Inc. (Nasdaq: XGN) announced a $27.2 million 5-year term loan with Innovatus Capital Partners at an 8.0% interest rate, where 2.0% is paid in-kind. This amendment strengthens their relationship, aiming to enhance patient care for autoimmune diseases through innovative testing solutions. The updated terms were disclosed in a Current Report filed on October 25, 2021. The loan is expected to support Exagen's mission of improving patient outcomes and reducing healthcare costs amidst ongoing challenges within the healthcare landscape.

Exagen Inc. (Nasdaq: XGN) will present new research at the virtual ACR Convergence 2021 from November 6-9, 2021. This research focuses on the role of cell-bound complement activation products (CB-CAPs) in diagnosing and treating systemic lupus erythematosus (SLE). Chief Scientific Officer Anja Kammesheidt expressed pride in collaborating with key researchers. Notable presentations include studies examining the clinical utility of multianalyte assays and CB-CAPs in SLE evaluation. Exagen aims to enhance patient care through advanced diagnostic solutions.

Exagen Inc. (Nasdaq: XGN) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, are set to hold a virtual fireside chat on September 27 at 2:40 PM EDT. Interested individuals can access the live webcast through Exagen's website. The company is focused on providing innovative autoimmune testing solutions, particularly for conditions like rheumatoid arthritis and lupus, through its AVISE® brand and proprietary technology.

Exagen Inc. (Nasdaq: XGN) reported record financial results for Q2 2021, achieving total revenue of $12.8 million, a 43% year-over-year increase, and a 21% rise from Q1 2021. Revenue from the AVISE® CTD test reached $10.4 million, marking a 94% increase from the previous year. The company delivered 33,328 tests, reflecting an 80% growth year-over-year. Despite these gains, operating expenses rose to $18.5 million, leading to a net loss of $6.4 million. Exagen maintains its full-year revenue guidance of $47 million to $49 million.

Exagen Inc. (Nasdaq: XGN) has appointed Ms. Ana Hooker as an independent member of its Board of Directors, effective July 29, 2021. Hooker brings extensive experience in clinical laboratories, having held senior roles in organizations like Exact Sciences. The addition is expected to bolster Exagen's growth strategy in autoimmune testing solutions. Exagen aims to enhance patient care through innovative testing products under its AVISE® brand, focusing on complex autoimmune diseases.

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen (Nasdaq: XGN) will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. CEO Ron Rocca and CFO Kamal Adawi will host a virtual fireside chat on August 12 at 12:00 PM EST. The session can be accessed through Exagen’s website.

Exagen aims to advance care for autoimmune disease patients with innovative testing solutions, including products under its AVISE® brand. For more details, visit their website.

Exagen Inc. (Nasdaq: XGN) will announce its financial results for Q2 2021 on August 9, 2021, post-market close. Key executives, including CEO Ron Rocca and CFO Kamal Adawi, will lead a conference call at 4:30 PM Eastern Time to review the results. Interested parties can join the call by phone or through a webcast available on Exagen’s investor relations website. A replay of the call will be accessible until August 16, 2021. Exagen focuses on autoimmune testing solutions, aiming to enhance patient care through its AVISE® brand products.

Exagen Inc. (Nasdaq: XGN) announced the publication of a clinical utility study in Lupus & Science Medicine demonstrating the effectiveness of the AVISE Lupus test. Conducted with 12 rheumatology practices, the study revealed that the AVISE test enhances physician confidence in diagnosing systemic lupus erythematosus (SLE) and informs treatment decisions. The results showed increased certainty in SLE diagnoses with higher AVISE scores. Exagen aims to support rheumatologists in managing autoimmune diseases through innovative testing solutions.

Exagen Inc. (Nasdaq: XGN) announced that stockholders have elected Mr. Frank Stokes as an independent member of its Board of Directors during the Annual Meeting on June 17, 2021. Mr. Stokes will also chair the Audit Committee. His experience as a CFO and investment banker, particularly in the life sciences sector, is expected to contribute significantly to Exagen's growth strategy. He aims to enhance Exagen's commitment to improving patient care through innovative autoimmune testing solutions.